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1. BACKGROUND 
Idiopathic pulmonary fibrosis (IPF) is a rare parenchymal lung disease characterized by a 
chronic progressive interstitial fibrosis which has a worse prognosis than other forms of chronic 
interstitial pneumonia. The median survival time is about 2-3 years from diagnosis and varies 
from a few months to several years. Natural history of IPF is unpredictable and the course of 
disease can be highly variable. An early and accurate diagnosis of IPF is important to enable 
the initiation of specific therapies to reduce disease progression. Establishing the diagnosis of 
IPF remains challenging; therefore international guidelines advocate the importance of a 
multidisciplinary team in the initial assessment of patients with suspected IPF. Many biomarkers 
have been studied to solve this without real success. 
2. AIMS OF THE STUDY  
 
The aim of this study was to evaluate surrogate new biomarkers by comparing their levels in 
serum and induced from patients with IPF, other fibrosis of known origin, COPD (chronic 




We analysed the serum and the induced sputum of 100 patients divided in 4 groups. The first 
group was the control group with healthy subjects (n=39). The second was a group of COPD 
(n=25) diagnosed according to the 2014 GOLD recommendation. The third group was the IPF 
group (n=17). The diagnosis of this group was made following the international recommendation 
of the ATS (1) using the pulmonary function tests, the chest-CT, the bronchoalveolar lavage 
(when available), the biopsy (when available) and the disease history. All cases were discussed 
in our multidisciplinary team composed of pulmonologists, rehabilitation specialised 
pulmonologists, rheumatologists, radiologists, pathologists, a work related disease doctor and 
an immunologist. Only one patient was already treated with a specific IPF therapy (pirfenidone). 
The last group was the non-IPF group (n=19) composed of multiples interstitial lung diseases at 
different time of their evolution without taking in consideration the received treatment (also 
discussed in our multidisciplinary team). This included NSIP (non specific interstitial pneumonia) 
(n=4), sarcoidosis (n=6), hypersensitivity pneumonitis (n=1), connective tissue disease (n=5), 
anthracosilicosis (n=1), and others of unknown origin (n=2). 
 
Venous blood was collected in Vacutainer tubes from an antecubital site. Blood cell values 
included hemoglobin, platelet count, WBC count, and the differential leukocyte count, fibrinogen 
and C-reactive protein (CRP) levels were determined by the routine hospital laboratory.  
Sputum induction and processing were performed according to a technique used in routine in 
our asthma clinic (2), and a differential leukocyte count was obtained using a cytospin stained 
with Rapi Diff II (Atom Scientific, Manchester UK) on 500 non squamous cells.  
We analysed several biomarkers assumed to be critical growth factors by commercially 
available immunoassays (ELISA) in blood and sputum: TGFβ, IGF1 (Insulin-like growth factor), 
IGF2, IGFBP1 (Insulin-like growth factor binding protein), IGFBP2, IGFBP3 and IL-8.  
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4. RESULTS 
 
Serum, but not sputum, IGFBP2 levels are significantly higher in the IPF group and the non IPF 
group than in healthy subjects (p<0.01) (Table 1, Graph 1). This is not linked with a high level of 
IGF1 or IGF2 meaning that this is not an IGF mediated phenomenon. Serum IGFBP2 in IPF 
was not correlated with levels of IGFBP2 in induced sputum. The ratio IGF2/IGFBP2 in the 
serum of IPF patients strongly correlated with the severity of the disease assessed by 
FVC(r=0,8144; p<0,05). The ROC curve analysis (Graph 2) showed that IGFBP2 in serum 
could be discriminant between the IPF group an non IPF group with a sensitivity of 92% and a 
specificity of 90% (Area under ROC curve: 0.91) with the best cutpoint at 49 ng/ml.  
 







Level in serum          
  Healthy subjects COPD IPF Non IPF 
  nb = 31 nb = 25 nb = 7 nb = 9 
tgf-beta (pg/ml) 27195,5(6069,6) 26591,3(8686,5) 25024,1(7438,6) 28041,4(8856) 
IL-8 (pg/ml) 4,4(1-37,7) 2,9(0-18,1) 6,8(4,3-27,4) 8,8(4,5-57,6) 
igfbp-1 (pg/ml) 8(0,1-179,6) 9,4(1,7-195,6) 31,6(3,5-110,2) 13,7(4,2-30,6) 
igfbp-2 (ng/ml) 15(4,6-102,8) 29,3(9,9-89,8) 73,7(48-145,6) 41,3(22,1-89,2) 
igfbp-3 (ng/ml) 32(18,6-63) 28,7(16-48,4) 39(20,3-60,6) 34(27,5-73,4) 
igf-1 ((ng/ml) 68,7(33,2-196,5) 52,1(18,6-199,8) 44,4(0-108,8) 78,6(25-117,4) 
igf-2 (ng/ml) 1084(668-4258,6) 1568(516-7895,7) 1405,5(400-3131,8) 1128,8(740-3175,9) 
ratio igf2/igfbp1 187,5(12,2-21652,3) 158,9(8,2-5470,4) 55,7(5-432,5) 162,7(48,6-994) 
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ratio igf2/igfbp2 110,6(18,9-522,4) 105,6(18-865,1) 21,9(6,8-58,2) 44,3(22,6-106,4) 
ratio igf2/igfbp3 51,4(18,7-220,9) 133(37,9-317,5) 46,6(14,6-136,9) 48,3(31,1-137) 
ratio igf1/igfbp1 9,9(0,7-1611,8) 3,8(0,2-112,6) 1,5(0-24) 5,8(1,8-36,1) 
ratio igf1/igfbp2 5,067(1,368-34,008) 1,844(0,517-17,808) 0,666(0-1,756) 2,432(0,704-3,756) 
ratio igf1/igfbp3 2,8(1,076-4,695) 2,69(1,44-6,536) 1,513(0-3,549) 2,401(0,971-4,981) 
résults are expressed en médian 





Serum IGFBP2 could be a new interesting discriminant biomarker to identify and grade the 
severity of idiopathic pulmonary fibrosis. This observation is highly interesting and could lead to 
a new diagnostic algorithm. 
 
